Ultragenyx (RARE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Ultragenyx stock (RARE) is currently trading at $18.50. Ultragenyx PS ratio (Price-to-Sales) is 2.85. Analyst consensus price target for RARE is $54.25. WallStSmart rates RARE as Sell.
- RARE PE ratio analysis and historical PE chart
- RARE PS ratio (Price-to-Sales) history and trend
- RARE intrinsic value — DCF, Graham Number, EPV models
- RARE stock price prediction 2025 2026 2027 2028 2029 2030
- RARE fair value vs current price
- RARE insider transactions and insider buying
- Is RARE undervalued or overvalued?
- Ultragenyx financial analysis — revenue, earnings, cash flow
- RARE Piotroski F-Score and Altman Z-Score
- RARE analyst price target and Smart Rating
Ultragenyx
📊 No data available
Try selecting a different time range
Smart Analysis
Ultragenyx (RARE) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Ultragenyx (RARE) Key Strengths (2)
100.84% of shares held by major funds and institutions
Strong revenue growth at 25.90% annually
Supporting Valuation Data
Ultragenyx (RARE) Areas to Watch (7)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 247.7x book value
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.85x sales
Ultragenyx (RARE) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Revenue Growth. Growth metrics are encouraging with Revenue Growth at 25.90%.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (2.85), Price/Book (247.70) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -608.00%, Operating Margin at -54.60%, Profit Margin at -85.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -608.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 25.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RARE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RARE's Price-to-Sales ratio of 2.85x trades at a deep discount to its historical average of 293.03x (0th percentile). The current valuation is 100% below its historical high of 3134.56x set in Aug 2018, and 0% above its historical low of 2.85x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~6.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Ultragenyx (RARE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Ultragenyx is a strong growth company balancing expansion with improving profitability. Revenue reached 673M with 26% growth year-over-year. The company is currently unprofitable, posting a -85.4% profit margin.
Key Findings
Revenue growing at 26% YoY, reaching 673M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 30% of revenue (203M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -85.4% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -101M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Ultragenyx maintain 26%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Ultragenyx.
Bottom Line
Ultragenyx offers an attractive blend of growth (26% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Ultragenyx(RARE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.